
EQUITY INSTRUMENTS

Track value creation. Defend every mark.

Most equity losses are not surprises at exit. The signals — budget misses, management changes, thesis assumptions that quietly stopped holding — were present in the portfolio for months. Basis provides the managed oversight layer that tracks investee performance against plan, monitors thesis compliance, maintains continuous valuation evidence, and prepares analyst-reviewed packs — so your team can focus on the decisions that require genuine judgement.

PREVIOUSLY WORKED WITH

IFC | J.P. Morgan | United Nations | National Treasury | Bopa Moruo

THE SERVICE

Managed equity oversight, delivered every cycle.

Most equity losses are not surprises at exit. The signals — budget misses, management changes, thesis assumptions that quietly stopped holding — were present in the portfolio for months. The problem is that no structured layer was watching them.

Basis provides the managed oversight layer that tracks investee performance against plan, monitors thesis compliance, maintains continuous valuation evidence, and prepares analyst-reviewed packs for the companies that need attention — so your team can focus on the decisions that require genuine judgement.

WHAT THIS SERVICE COVERS

- Investee performance vs. budget and plan
- Investment thesis compliance tracking
- KPI trend monitoring per company per cycle
- Board pack receipt and information rights oversight
- Valuation evidence and IPEV-aligned support
- Management team and key person risk tracking
- Exit readiness indicators and scoring
- LP and IC reporting pack preparation

8

Investment structure types covered across the equity portfolio

12

Performance dimensions tracked per investee per cycle

Monthly

Managed oversight rhythm delivered to your team

4-step

Diagnostic process — begin with a single portfolio cohort

WHY THIS MATTERS

Most equity portfolios are well-originated. The problem is what happens after the investment closes.

01 — THE THESIS DRIFT PROBLEM

Investment theses break months before anyone names it

Theses are documented carefully at entry and then rarely revisited against evolving company performance. Revenue assumptions slip, market expansion stalls, management changes — and the team continues working from a narrative the evidence no longer supports. By exit, the divergence has compounded. The right time to catch it was quarter three, not the year before sale.

02 — THE REPORTING GAP

Board packs arrive. Oversight is something different.

Portfolio companies submit board packs on schedule. But receiving a pack is not the same as monitoring performance. Revenue vs. budget, EBITDA margin trends, working capital movement, and KPI tracking against plan require a separate analytical layer — one that most investment teams lack the bandwidth to apply consistently across the full portfolio between board meetings.

03 — THE VALUATION EVIDENCE PROBLEM

IPEV-compliant marks need evidence built ahead of time

Quarterly valuations need to be defensible — to auditors, to LPs, and to regulators who are increasingly focused on private market mark discipline. Assembling the evidence under quarter-end pressure is slow, incomplete, and carries audit risk. The evidence needs to exist before the conversation starts, not be constructed after it is already on the table.

"The goal is not to catch the decline at exit. It is to ensure that every deviation from plan has been seen, assessed, and either escalated or explained — not discovered when it is too late to act."

Oversight across the full range of private equity and equity-linked structures.

Each structure type carries different monitoring requirements, governance mechanics, and value creation levers. We apply the right framework to each one.

<p>Direct Equity</p> <p>Performance vs. plan, KPI tracking, thesis compliance, management team assessment, exit readiness.</p>	<p>Preferred Equity</p> <p>Preference coverage, liquidation waterfall position, anti-dilution mechanics, ratchet trigger monitoring.</p>	<p>Convertible Instruments</p> <p>Conversion trigger tracking, valuation cap headroom, maturity risk, next-round dilution impact.</p>	<p>Venture & Growth Equity</p> <p>Burn rate, runway, milestone achievement, ARR growth vs. plan, fundraising readiness and timing.</p>
<p>Buyout Equity</p> <p>EBITDA vs. budget, leverage covenant headroom, debt service coverage, exit multiple tracking.</p>	<p>Co-Investments</p> <p>Lead manager reporting quality, independent performance verification, information rights compliance.</p>	<p>Secondary Positions</p> <p>NAV validation, underlying portfolio visibility, vintage performance, liquidity and exit timeline.</p>	<p>Management Incentive Structures</p> <p>Hurdle and vesting compliance, leaver provisions, good/bad leaver events, dilution and alignment monitoring.</p>

The oversight layer across the equity portfolio.

We help investment teams see thesis drift earlier, maintain valuation discipline, and sustain the governance standard the portfolio requires — regardless of internal bandwidth.

<p>Investee performance vs. budget and plan</p>	<p>Revenue and EBITDA trend analysis</p>	<p>KPI tracking per company per cycle</p>
<p>Board pack receipt and review log</p>	<p>Information rights compliance</p>	<p>Management team changes and key person risk</p>
<p>Strategic milestone tracking</p>	<p>Investment thesis compliance review</p>	<p>Valuation evidence and IPEV support</p>
<p>Cap table and dilution monitoring</p>	<p>Exit readiness indicators and scoring</p>	<p>LP and IC reporting pack preparation</p>

Why managed oversight outperforms internal bandwidth.

In-house portfolio monitoring depends on team capacity, consistent execution, and the right person looking at the right company at the right time. When any of these are stretched — and in active funds they frequently are — coverage drops, signals are missed, and valuations are harder to defend. Basis maintains the discipline regardless of internal pressure.

AREA	IN-HOUSE / TRADITIONAL	BASIS PARTNERS
Performance vs. plan	<ul style="list-style-type: none"> Reviewed at board meetings and annual reviews. Budget variances accumulate between meetings without a structured tracking layer in place. 	<ul style="list-style-type: none"> Structured monthly tracking against budget and plan. Variance flags, trend analysis, and analyst commentary per investee each cycle.
Thesis compliance	<ul style="list-style-type: none"> Documented at entry and rarely revisited in structured form. Drift accumulates until it surfaces at a portfolio review or an LP question. 	<ul style="list-style-type: none"> Original thesis assumptions reviewed each cycle against current company data. Divergence flagged with analyst rationale before it compounds.
Valuation evidence	<ul style="list-style-type: none"> Assembled at quarter-end under pressure. Methodology is often retrospective and the audit trail incomplete when questioned by LPs or auditors. 	<ul style="list-style-type: none"> Built continuously throughout the cycle. IPEV-aligned evidence packs exist before the quarter-end conversation begins — not assembled after it starts.
Exit readiness	<ul style="list-style-type: none"> Assessed informally as exit approaches. No structured scoring or ongoing tracking against defined indicators across the portfolio. 	<ul style="list-style-type: none"> Tracked against defined indicators each cycle. Scoring per company, movement since last review, and readiness gaps flagged ahead of exit conversations.
KPI discipline	<ul style="list-style-type: none"> Dependent on what the company chooses to report. Missing or inconsistent KPI data is common and often not formally escalated. 	<ul style="list-style-type: none"> Tracked against an agreed KPI set per company. Missing data and unusual movements flagged as part of the managed reporting exceptions register.
LP and IC reporting	<ul style="list-style-type: none"> Time-intensive to produce. Quality and consistency depend on who is available and how stretched the team is at reporting time. 	<ul style="list-style-type: none"> Prepared as part of the managed service. Consistent format, structure, and quality each cycle — without internal resource pressure at quarter-end.
Management risk	<ul style="list-style-type: none"> Noted when changes happen. No structured assessment of key person dependency or management team movement as an ongoing signal. 	<ul style="list-style-type: none"> Monitored as part of each periodic review. Key person flags, management team changes, and dependency risks assessed and escalated with rationale.

AREA	IN-HOUSE / TRADITIONAL	BASIS PARTNERS
Coverage consistency	<ul style="list-style-type: none">– Varies with team capacity, portfolio size, deal flow pressure, and staff turnover. Quieter companies are routinely under-monitored.	<ul style="list-style-type: none">✓ Consistent monthly coverage across the full selected cohort, regardless of internal pressure, absences, or competing transaction activity.

WHAT YOU RECEIVE

A managed portfolio view. Every cycle.

01

Investee performance view

A structured view of each company's position against budget, plan, and agreed KPIs — with variance commentary and trend flags updated each review cycle.

- Revenue and EBITDA vs. budget per company
- KPI status and movement since last cycle
- Open issues and pending management actions

02

Thesis compliance report

A structured review of original investment assumptions against current company data — identifying where the thesis is holding, where it has drifted, and what that means for the position.

- Original assumption vs. current evidence
- Drift flags with analyst rationale
- Escalation recommendations where warranted

03

Valuation evidence pack

IPEV-aligned evidence built continuously throughout the cycle — ready for auditors, LPs, and internal IC before the quarter-end conversation begins.

- Methodology and supporting data per company
- Movement narrative since last mark
- Audit-ready evidence trail each quarter

04

Exit readiness scorecard

A scored view of each company's readiness across operational, financial, governance, and market indicators — updated each cycle and tracked against prior periods.

- Readiness score per indicator per company
- Movement and change since last review
- Gap flags and recommended actions

05

Portfolio governance log

A full record of board pack receipt, information rights compliance, management team changes, and open governance items across the portfolio.

- Board pack receipt and quality log
- Information rights exceptions
- Management changes and key person flags

06

LP and IC portfolio summary

Packs ready for quarterly LP reporting, IC reviews, and portfolio committee meetings — consistent format and quality each cycle, without internal resource pressure.

- LP-ready portfolio summary
- IC-ready company briefs
- Consistent format across all reporting periods

HOW WE START

We begin with a focused portfolio company diagnostic.

01

You select a cohort of portfolio companies.

Choose two to five companies that best represent the oversight challenge — a mix of performers, concerns, and upcoming exits is a useful starting point.

02

We work from your existing materials.

We work from the information you already have — IC papers, board packs, KPI reports, management updates, value creation plans, and financial statements.

03

We prepare the first performance and thesis view.

A full analyst-reviewed view across the selected cohort — performance vs. plan, thesis compliance, valuation evidence, governance log, and exit readiness.

04

You assess the quality before expanding.

Review the output with your team. If it adds value, we expand the mandate across the full portfolio. If not, you keep all outputs, frameworks, and templates regardless.

YOUR INVESTMENT AUTHORITY STAYS WITH YOU

Basis provides the managed oversight layer around the judgement your team already owns. We do not make investment decisions, recommend disposals, or interact with portfolio companies directly. We make sure your team has the performance data, thesis tracking, and valuation evidence needed to make those decisions well.

ONGOING RHYTHM

If useful after the diagnostic, we continue as a managed monthly or quarterly oversight service. Frequency and scope are set by what your portfolio requires — aligned to your reporting calendar, not a fixed package.

NO COMMITMENT REQUIRED

The diagnostic is the start of the engagement, not a sales step. You see real analyst work on your actual portfolio companies before deciding whether to continue.

Ready to see what is moving across your portfolio?

Start with a portfolio company diagnostic. No commitment required beyond the first review. We work from your existing files and deliver a full analyst-reviewed performance and thesis view within agreed timelines.

EMAIL advisory@basispartners.co.za

LOCATION Johannesburg, South Africa